FUJIFILM Irvine Scientific, Inc., a global provider for the manufacture of cell culture solutions for the life science and medical markets, entered an agreement to sell its Medical Media Business Unit (MBU) to Astorg, a European private equity firm with a focus on global healthcare investments. This acquisition expands Astorg’s reproductive health business.

The sale is expected to close on April 1, 2025.

As part of the Life Sciences Business Division of FUJIFILM Corp., FUJIFILM Irvine Scientific is focused on being a supplier to the life science market. The MBU consists of products used for in vitro fertilization (IVF), infertility research, and cytogenetic analysis. The sale of the MBU aims to accelerate future investments towards market growth and further enhance FUJIFILM Irvine Scientific’s focus on life sciences.

“After careful consideration, we made a strategic decision to sell the MBU because we recognized the different trajectories and needs of our businesses. This move allows for continued focus on our life sciences businesses within Fujifilm, and for the MBU to thrive under Astorg,” said Tim Mullane, president, FUJIFILM Irvine Scientific. “Astorg has demonstrated a strong commitment to building capabilities to support the IVF market. We will work closely with Astorg to ensure a smooth transition of the MBU and seamless support for global IVF customers.”